Base pivot gains traction, but ibuprofen overhang and cost headwinds cap upside

Delivered 381.6 Cr, 19.6% YoY growth

Base 307 Cr (+24% YoY) but gross margin 51.3% vs prior 54%+ due to 17-18 Cr cost pass-through

PAT 16.3 Cr confirmed, EBITDA ~62 Cr (implied margin 16.2%), need prior comparisons to verify

Flat QoQ revenue (-1.5% consolidated, likely -2 to -3% for base) despite 24% YoY; Q1 seasonally weak in API

Management expects -12% to continue, with ₹10-15 Cr quarterly loss normalized

Q1 FY27 base revenue ₹307 Cr (+24% YoY), up from prior ₹248 Cr (Q1 FY26). Crossed ₹300 Cr plateau. Prior guidance vague; now shows sustained momentum at higher level.

Net debt reduced ₹135 Cr in Q1 (22% decline to ₹479 Cr). ₹100 Cr from rights issue, ₹35 Cr from ops cash flow. Ahead of prior implied 1.7x target for end-FY27.

Q4 guided 'H1 FY27' decision; Q1 reaffirmed same H1 timeline with no new progress. ~₹700 Cr deployed, expected to run at ₹10-15 Cr quarterly loss going forward—no upside scenario articulated.

25% EBITDA margin ±1% for base business restated (Q4 guidance). Q1 delivered 23.5% (72/307), compressed by cost headwinds and product mix. Guidance reaffirmed but not upgraded.

Base business capacity utilization 70% across three sites (Cuddalore, Bangalore, Ambernath). Vizag remains mothballed. Implies room for ₹40 Cr debottlenecking capex to yield 20-30% capacity gains on high-margin lines.

Three levers: (1) expand existing business, seed new; (2) drive operational efficiency via debottlenecking, not greenfield; (3) optimize working capital for free cash generation.

On track for H1 solution. Working toward optimum solution; fairly confident it will come out by H1. Address details in September.

Most growth from business expansion and gross margin expansion via incremental volumes. Limited operating leverage; will focus on top-line growth combined with margin expansion.

50-55% comfortable range. Product mix, quarterly linearity, and cost pass-through all vary. Adjusted for ₹17-18 Cr cost pass-through, base business margin 54.5%, in line with prior quarters.

~₹30 Cr revenue from cost pass-through. Good customer relationships; most accepting price increases after transparent communication of cost norms. Few resistant; managing dynamic.

~₹700 Cr deployed.

Commodity business with solvent supply constraints. Expect to sustain at ₹10-15 Cr quarterly EBITDA loss going forward, similar to Q1 run rate.

West Asia crisis is ongoing challenge: raw material availability and pricing both pressured. Transparent with customers on incremental costs; confident on maintaining gross margin absolute value. US tariffs: no formal policy yet; awaiting scope clarification (formulations only vs APIs).

Q1 seasonally weak in API. Product basket 50 products; 15-16 drive 75% revenue. YoY growth 24% more meaningful (organic 18-19% after cost adjustment). Base business now at ₹300 Cr+ plateau vs ₹245-248 Cr prior.

Internally targeting net debt free by FY29. Will have gross debt on books but net debt zero. Slightly hesitant to give tighter timeline; no formal guidance beyond FY29.

25% plus/minus 1% should be margin profile for base business EBITDA. Reaffirming prior guidance; not committing to exceed.

All decisions reconsidered if profitable. But ibuprofen is commodity; margins never match base business. Have other manufacturers; dynamics won't change. Margins fundamental constraint.

Recovering entire ₹700 Cr unlikely. Finalizing next steps by Q2 results; will share clarity then on cutoff/write-down.

Worked down rigorously for turnaround. Not expecting efficiency hit from revenue growth; working on S&OP to improve inventory. Aspiration is to improve efficiency, not sacrifice it for growth.

Greenfield not in plan (once bitten, twice shy). FY27 ₹55-60 Cr: ₹40 Cr debottlenecking (high-margin lines 20-30% capacity gains, 2-3 quarter payback), ₹10-15 Cr maintenance. FY28-29 similar: ₹40-50 Cr annually. Vizag remains mothballed; decision pending by Q2.

New reactors have better operational days, reduced leaks/wear-tear. Absolute output volume increases (operational days improve). Not necessarily yield improvement, but higher throughput.

Base business three sites (Cuddalore, Bangalore, Ambernath): ~70% average capacity utilization. Vizag mothballed; plan to retrofit for CRAMS on hold pending H1 decision. CRAMS demerger status TBD.

Policy not to comment on individuals. Question skipped.

Ibuprofen not manufactured via enzymatic route. Correction made.

Growth from: (1) debottlenecking capex (FY26 onwards) driving volumes in high-margin products; (2) geographic expansion / new business wins. Organic growth 18-19% YoY (after price adjustment). Confident of sustaining at least 10% going forward.

Refrain from 5-year outlook due to dynamic external environment. Past 5 quarters show new level reached (last 2 quarters at ₹300+ Cr base revenue; prior 3 at lower level). Hope to sustain or grow from new level. Margins: 52-55% gross margin range; 25% ±1% EBITDA margin.

On track for H1 solution. Hopeful to find solution by H1 timeline. Details in September.

Q1 tactical play due to reduced solvent supply and higher demand. Not expecting long-term improvement; expect average of ₹10-15 Cr quarterly EBITDA loss to sustain.

Customer relationships equivalent. Difference: ibuprofen commodity-driven, low value-chain position. Base business non-high-volume but complex manufacturing molecules with better margin/pricing profile.

Three pillars: (1) revenue growth: base business ₹250-245 Cr → ₹300+ Cr; (2) profitability: base business EBITDA ₹55 Cr → ₹70+ Cr (25.6% margin); (3) balance sheet: net debt reduced ₹135 Cr (22% reduction in 6-7 months).

No strategic decision yet. Looking at options. H1 FY27 decision will provide clarity. Proceed allocation TBD.

Primary risk: West Asia crisis impact—managed so far but limited working capital means every rupee critical. Macro environment unpredictable. Second: raw material availability constraints (line shutdowns). Third: customer acceptance of price increases (not all willing; some resistance). Risks not in control but manageable.

Mostly referring to base business. Q4 call guided 10% growth for base business for FY27. Not providing formal outlook; 10% is conservative given 24% delivered this quarter.

Conservative given 24% delivered Q1 FY27. No formal FY27 target, but reaffirmed in multiple Q&A responses. Assumes normalization post-West Asia crisis

Reaffirmed from Q4 FY26 call. Q1 FY27 delivered 23.5% (below range due to cost headwinds); management expects reversion to 25% range once raw material costs normalize

Q1 delivered 51.3% (adjusted 54.5% ex cost pass-through). Comfortable with range; aspiration to reach 55% end of range

FY27: ₹40 Cr debottlenecking (20-30% capacity gains, 2-3 quarter payback), ₹10-15 Cr maintenance. Similar split for FY28-29. No greenfield planned

Solvent shortage from West Asia crisis causing intermittent line shutdowns, raw material availability constraints, and 30% cost inflation. Some customers accepting price increases, others resistant. Risk extends into H2 FY27 at least

₹700 Cr capital deployed in ibuprofen business (debt + equity) earning -12% EBITDA margin with ₹10-15 Cr quarterly loss normalized. No clear exit plan articulated. Strategic review deferred to H1 FY27. Full capital recovery "slightly farfetched" per CFO. Risk of 20-30% write-down or divestment at discounted value

Base business 24% YoY growth delivered, but QoQ revenue flat (-1.5% consolidated, likely -2-3% base). Q1 seasonally weak in API. Post-West Asia normalization, if cost pass-through reverses and volumes don't accelerate, risk of growth falling below 10% guided level. Product mix (50-60 products, 15-16 drive 75%) adds concentration risk

Some customers resistant to accepting cost price increases amid West Asia crisis. If major customers shift to competitors or reduce orders, revenue could compress. Customer relationship strength not quantified; only assurance given is "historically strong quality record"

Net debt still elevated at 1.9x annualized EBITDA (₹479 Cr). If base business growth slows below 10% or ibuprofen decision requires capex write-down, interest burden could strain margins. Refinancing risk if credit tightens